MYD88 and breast carcinoma: Commencing with a stratification of breast cancer patients by their molecular subtypes, we discerned a pronounced elevation in MyD88 expression within the basal and normal-like subtypes when juxtaposed with the Luminal A, Luminal B, and HER2-enriched subtypes (Figure 1A).